



Caribou Biosciences to Participate in Upcoming Investor Conferences

February 18, 2025

BERKELEY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- [Caribou Biosciences, Inc.](#) (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in the following investor conferences:

- **H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference**

February 25, 2025, fireside chat at 11:30 AM ET

[Webcast](#)

- **Leerink Global Healthcare Conference**

March 11, 2025, fireside chat at 1:40 PM ET

[Webcast](#)

For more information, visit the [Events](#) page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contacts:

Investors:

Amy Figueroa, CFA

investor.relations@cariboubio.com

Media:

Peggy Vorwald, PhD

media@cariboubio.com